Non-human primate models of multiple sclerosis

Immunological Reviews

Volumn 183, Issue , 2001, Pages 173-185

  Brok, Herbert P M ^a   Bauer, Jan ^b   Jonker, Margreet ^a   Blezer, Erwin ^c   Amor, Sandra ^a   Bontrop, Ronald E ^a,d   Laman, Jon D ^e   'T Hart, Bert A ^a,b,c,f  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b UNIVERSITY OF VIENNA   (Austria)

^c UTRECHT UNIVERSITY   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^f Dept Immunobiology ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; HISTOPATHOLOGY; IMAGE ANALYSIS; IMAGING; IMMUNOPATHOGENESIS; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; REVIEW;

ANIMALS; BRAIN; CALLITHRIX; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GLYCOPROTEINS; MACACA; MALE; MULTIPLE SCLEROSIS; PEPTIDE FRAGMENTS;

EID: 0035676311     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2001.1830114.x     Document Type: Review

References (81)

1. Evolution of major histocompatibility complex polymorphisms and T cell receptor diversity in primates
2. Major histocompatibility complex class II polymorphisms in primates
3. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
4. Cellular immune reactivity within the CNS
5. Apoptosis in brain-specific autoimmune diseases
6. Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis
7. In healthy primates circulating autoreactive T-cells mediate autoimmune disease
8. Encephalitogenic potential of myelin-basic protein-specific T cells isolated from normal rhesus macaques
9. Axonal transection in the lesions of multiple sclerosis
10. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability
11. Cytomegalovirus isolation from a chimpanzee with acute demyelinating disease after inoculation of multiple sclerosis brain cells
12. Acute demyelinating disease in a chimpanzee three years after inoculation of brain cells from a patient with MS
13. Infection and disease induced in chimpanzees with 6/94, a parainfluenza type 1 virus isolated from human multiple sclerosis brain
14. No mouse PMN leukocyte depression after inoculation with brain tissue from multiple sclerosis or spongiform encephalopathies
15. Multiple sclerosis and HLA: Is the susceptibility gene really HLA-DR or -DQ?
16. T-cell recognition of myelin basic protein
17. Evolutionary conservation of Mhc-DR/peptide/T cell interactions in primates
18. Activation of a myelin basic protein specific human T cell clone by antigen-presenting cells from rhesus monkeys
19. Rhesus monkeys are highly susceptible to experimental autoimmune encephalomyelitis induced by myelin/oligodendrocyte glycoprotein (MOG). Characterization of immunodominant MOG T- and B-cell epitopes
20. Herpesviruses of primates: An introduction
21. Observations on the attempts to produce acute-disseminated encephalomyelitis in monkeys
22. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys
23. Experimental allergic encephalomyelitis (EAE) in nonhuman primates: A model of multiple sclerosis
24. Magnetic resonance imaging of experimental allergic encephalomyelitis in primates
25. Myelin basic protein treatment of experimental allergic encephalomyelitis
26. Species-restricted encephalitogenic determinants
27. Hyperacute experimental allergic encephalomyelitis in rhesus monkeys as a model of acute necrotizing hemorrhagic encephalomyelitis
28. Identification of an Mhc-DPB1 allele involved in susceptibility to experimental autoimmune encephalomyelitis in rhesus macaques
29. Experimental allergic encephalomyelitis in rhesus monkeys: II. Treatment of EAE with anti-T lymphocyte subset monoclonal antibodies
30. In vivo administration of anti-CD4 monoclonal antibody prolongs survival in long-tailed macaques with experimental allergic encephalomyelitis
31. Autoimmunity in non-human primates: The role of major histocompatibility complex and T cells, and implications for therapy
32. Depletion of T lymphocytes with immunotoxin retards the progress of experimental allergic encephalomyelitis in rhesus monkeys
33. Conformation of a heptadecapeptide comprising the segment encephalitogenic in rhesus monkey
34. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis
35. Preparation of highly purified myelin oligodendrocyte glycoprotein in quantities sufficient for encephalogenicity and immunogenicity studies
36. T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin/ oligodendrocyte glycoprotein
37. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: A comparative study
38. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein
39. HLA-DP; a class II restriction molecule involved in epitope spreading during the development of multiple sclerosis
40. Actively and passively induced experimental autoimmune encephalomyelitis in common marmosets: A new model for multiple sclerosis
41. Characterization of the TCRB chain repertoire in the New World monkey Callithrix jacchus
42. The common marmoset: A new world monkey species with limited MHC class II variability
43. Creation of a model for multiple sclerosis in Callithrix jacchus marmosets
44. A new primate model for multiple sclerosis
45. The pathology of multiple sclerosis and its evolution
46. Histopathological characterization of magnetic resonance imaging-detectable brain white matter lesions in a primate model of multiple sclerosis. A correlative study in the experimental autoimmune encephalomyelitis model in common marmosets (Callithrix jacchus)
47. Determinant spreading assoociated with demyelination in a nonhuman primate model of multiple sclerosis
48. Myelin/oligodendrocyte glycoprotein (MOG) induced autoimmune encephalomyelitis in the common marmoset: Presentation of an encephalitogenic T cell epitope by the monomorphic MHC class II molecule Caja-DRB*W1201
49. Serial MR imaging of experimental autoimmune encephalomyelitis induced by human white matter or by chimeric myelin-basic and proteolipid protein in the common marmoset
50. Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix jacchus)
51. Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimiric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses
52. Axonal degeneration is an early pathological feature in autoimmune mediated demyelination in mice
53. Multiple sclerosis and chronic encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive and remyelinated lesions
54. Demyelination and axonal damage in a non-human primate model of multiple sclerosis
55. Acquired mitochondrial impairment as a cause of optic nerve disease
56. Inhibition of energy metabolsim alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative
57. Metabolic activation of phenols by stimulated neutrophils: A concept for a selective type of anti-inflammatory drug
58. Molecular mechanisms of ischemic damage of spinal cord
59. g7) mice
60. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein
61. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate
62. Identification of autoantibodies associated with myelin damage in multiple sclerosis
63. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesion: A case for antigen-specific antibody mediation
64. The functional significance of epitope spreading and its regulation by costimulatory molecules
65. Spreading of T-cell autoimmunity to cryptic determinants of an autooantigen
66. Immune focussing vs diversification and their connection to immune regulation
67. Lymphocyte targeting of the central nervous system: A review of afferent and efferent CNS-immune pathways
68. Lymphocyte targeting of the brain in adoptive transfer cryolesion EAE
69. The importance of non-human primates for preclinical testing of immunosuppressive monoclonal antibodies
70. Safety and efficacy of therapeutic monoclonal antibodies in clinical therapy
71. Nonhuman primate models to evaluate vaccine safety and immunogenicity
72. Immunogenicity of biopharmaceuticals in laboratory animals
73. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins
74. Experimental autoimmune encephalomyelitis: Immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors
75. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis
76. The use of monoclonal antibodies for treatment of autoimmune disease
77. The ups and downs of multiple sclerosis therapeutics
78. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
79. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-412: Results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial
80. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
81. Late complications of immune deviation therapy in a nonhuman primate